The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
|Videos|June 2, 2017
Dr. Barber on Neoadjuvant Chemotherapy in Ovarian Cancer
Author(s)Emma Barber, MD
Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses neoadjuvant chemotherapy lowering readmission rates for patients with ovarian cancer.
Advertisement
Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses neoadjuvant chemotherapy lowering readmission rates for patients with ovarian cancer.
According to Barber, the use of neoadjuvant chemotherapy will reduce the readmission rate, even in populations that are at higher risks for readmission.
It is important to individualize treatments to decide what will be benefit the patient long-term, explains Barber.
Advertisement
Related to this article
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL
4
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
5